Copyright
©The Author(s) 2018.
World J Transplantation. Sep 10, 2018; 8(5): 178-187
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.178
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.178
PE-IVIG-RTX group (n = 9) | Control group (n = 12) | |
Infections | ||
Pyelonephritis and urinary tract infections | 1 | 0 |
Gastrointestinal (diarrhea, ileitis) | 2 | 0 |
Respiratory infection (bronchiolitis) | 1 | 0 |
Acute cholecystitis | 1 | 0 |
Cancers | 0 | 2 |
Death | 1 | 1 |
- Citation: Mella A, Gallo E, Messina M, Caorsi C, Amoroso A, Gontero P, Verri A, Maletta F, Barreca A, Fop F, Biancone L. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results. World J Transplantation 2018; 8(5): 178-187
- URL: https://www.wjgnet.com/2220-3230/full/v8/i5/178.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i5.178